Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680579 | 0.88 | PLA2G2C (0.37) | PLA2G2CCYP2C19TLR2CES2 | |
| SCHEMBL25962721 | 0.86 | PLA2G2C (0.39) | PLA2G2CCYP2C19TLR2CES2MMP8 | |
| SCHEMBL23613258 | 0.84 | CYP2D6 (0.35) | PLA2G2CCYP2D6CYP2C19TLR2MMP1 | |
| SCHEMBL20883265 | 0.78 | EPHX1 (0.51) | CYP2D6CYP2C19CES2EPHX1 | |
| SCHEMBL20883279 | 0.78 | EPHX1 (0.51) | CYP2D6CYP2C19CES2EPHX1 | |
| SCHEMBL23613458 | 0.78 | CYP2D6 (0.38) | CYP2D6CYP2C19MLYCDCES2MMP1 | |
| SCHEMBL23613454 | 0.71 | PLA2G2C (0.30) | PLA2G2C | |
| SCHEMBL23872929 | 0.71 | CYP2D6 (0.34) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL13373645 | 0.70 | LMNA (0.42) | CYP2D6CYP2C19TLR2MMP1MMP8 | |
| SCHEMBL23872743 | 0.70 | CNR1 (0.36) | PLA2G2CCYP2C19TLR2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | PLA2G2C 522/4885CYP2D6 216/4885CYP2C19 127/4885 |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | PLA2G2C 522/4885CYP2D6 216/4885CYP2C19 127/4885 |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | PLA2G2C 522/4885CYP2D6 216/4885CYP2C19 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.